Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. Cihan Erol , Ali Nahit Sendur Mehmet , Irem Bilgetekin , Duygu Bayir Garbioglu , Jamshid Hamdard , Sinem Akbas , Mutlu Hizal , Cagatay Arslan , Alper Sevinc , Ahmet Kucukarda , Dilek Erdem , Seda Kahraman , Emre Cakir , Aykut Demirkiran , Sercan On , Izzet Dogan , Atike Pinar Erdogan , Sinan Koca , Pinar Kubilay , Orhan Onder Eren , Ebru Cilbir , Emir Celik , Murat Araz , Deniz Tataroglu Ozyukseler , Mahmut Emre Yildirim , Aykut Bahceci , Halil Taskaynatan , Abdilkerim Oyman , Gulhan Ipek Deniz , Serkan Menekse , Engin Kut , Ahmet Gulmez , Abdullah Sakin , Erdinc Nayir , Ramazan Acar , Erdem Sen , Ali Inal , Serdar Turhal , Ali Osman Kaya , Semra Paydas , Didem Tastekin , Ilhan Hacibekiroglu , Irfan Cincin , Ahmet Bilici , Nil Molinas Mandel , Didem Sener Dede , Muhammed Bulent Akinci , Berna Oksuzoglu , Dogan Uncu , Bulent Yalcin , Mehmet Artac Journal of cancer research and therapeutics（2022）
摘要
Overall and PFS were similar in routine clinical practice compared to phase III pivotal VELOUR trial. However, response rates were found to be higher. It was observed that there were fewer adverse events compared to the VELOUR trial.
更多 查看译文
关键词
Aflibercept, clinical practice, colorectal cancer, real-life data, second-line
AI 理解论文
溯源树
样例
